Biocitech Life Science Park Welcomes Chem-X-Infinity and Spectralys Innovation
News Nov 25, 2008
Biocitech, the Paris life science technology park, announces that two new companies, Chem-X-Infinity and Spectralys Innovation, have become the park's 23rd and 24th residents. The new companies bring new strengths in chemistry and consulting to the life science industry.
Chem-X-Infinity sarl is specialized in the automated synthesis of libraries of organic molecules for the pharmaceutical and agrochemical industries. Founded in 2008, this company uses standard medicinal chemistry filters and molecular modeling tools including virtual screening and docking, to identify molecules whose chemical structure appears to be of interest.
Chem-X-Infinity sells from catalog on a semi-exclusive basis, offering to design exclusive focused chemical libraries. Chem-X-Infinity's products offer in vitro biological screening to accelerate the process of finding new active molecules.
"Biocitech is delighted to welcome Chem-X-Infinity and Spectralys Innovation, two companies who boost our activities in chemistry and R&D," said Biocitech CEO, Jacques Lhomel. "The three new arrivals this fall demonstrate our success and our drive for expansion, generating the need to double the area of the park. Expansion work is planned to start at the end of 2009 for completion in 2011."
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE
Lab Innovations returns to the NEC, Bimingham , UKNews
Save the date for the UK’s only lab-dedicated exhibition showcase!READ MORE
Comments | 0 ADD COMMENT
International Conference on Biobetters and Regulatory Affairs
Jun 27 - Jun 28, 2018